HBOT is FDA-approved for diabetic foot ulcer support. The Zhang 2022 meta-analysis of 20 RCTs (1,263 patients) found significantly higher complete-healing rates, shorter healing times, and lower major-amputation rates with HBOT vs. standard care.
Hyperbaric oxygen for diabetic foot ulcers is one of the established, clinically recognized uses of HBOT, delivered in supervised medical settings at clinical pressures (typically ~2.0–2.5 ATA). The rationale is well understood: chronic diabetic wounds are often hypoxic, and raising dissolved oxygen supports the angiogenesis and tissue repair that healing requires. Major hyperbaric-medicine bodies list selected diabetic wounds among approved indications. Saturate does not yet hold a primary clinical trial for this indication in its library — a gap we have flagged for sourcing — so we point to the authoritative indications list below rather than overstate a specific result.
Related conditions & guides
Explore HBOT in cancer survivorship, and our guide to understanding ATA pressure.
Authoritative reference
For external context, see the Cochrane review of HBOT for chronic wounds (PubMed).
This content is for educational purposes only and is not medical advice. Hyperbaric oxygen therapy carries genuine clinical risks and differs by pressure; consult a qualified clinician. Read our full medical disclaimer.